1 |
Leung KK, Deeb M, Fischer SE, Gulamhusein A. Recurrent Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Directions. Semin Liver Dis 2021;41:409-20. [PMID: 34182588 DOI: 10.1055/s-0041-1730950] [Reference Citation Analysis]
|
2 |
Kulkarni C, Murag S, Cholankeril G, Fardeen T, Mannalithara A, Lerrigo R, Kamal A, Ahmed A, Goel A, Sinha SR. Association of Anti-TNF Therapy With Increased Risk of Acute Cholangitis in Patients With Primary Sclerosing Cholangitis. Inflamm Bowel Dis 2021;27:1602-9. [PMID: 33300561 DOI: 10.1093/ibd/izaa317] [Reference Citation Analysis]
|
3 |
Aranake-Chrisinger J, Dassopoulos T, Yan Y, Nalbantoglu I. Primary sclerosing cholangitis associated colitis: Characterization of clinical, histologic features, and their associations with liver transplantation. World J Gastroenterol 2020; 26(28): 4126-4139 [PMID: 32821074 DOI: 10.3748/wjg.v26.i28.4126] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
4 |
Peverelle M, De Cruz P, Paleri S, Gow PJ. Impact of Inflammatory Bowel Disease and Azathioprine on Long-Term Outcomes After Liver Transplantation for Primary Sclerosing Cholangitis. Liver Transpl 2021;27:770-1. [PMID: 33569894 DOI: 10.1002/lt.26009] [Reference Citation Analysis]
|